bluebird bio reported Q3 2024 revenue of $10.6M, down from $12.3M YoY, with 57 patient starts completed and 17 more scheduled through 2024. The company has activated over 70 qualified treatment centers, with 40% having initiated or completed treatment for at least one patient. Commercial momentum is evidenced by 30 patient starts already scheduled for 2025.The company's cash position stood at $118.7M as of September 30, including $48M in restricted cash. Management expects current funds to last into Q1 2025 and anticipates reaching quarterly cash flow break-even in H2 2025, contingent on scaling to approximately 40 drug product deliveries per quarter and securing additional financing. Operating expenses showed improvement with R&D expenses decreasing to $23.2M from $58.5M YoY.The company has made significant progress in market access, with over half of U.S. states affirming coverage for LYFGENIA and multiple outcomes-based agreements in place with national commercial payers covering more than 200 million lives. Net loss for Q3 improved to $60.8M compared to $87.2M in the prior year.

bluebird bio reported Q3 2024 revenue of $10.6M, down from $12.3M YoY, with 57 patient starts completed and 17 more scheduled through 2024. The company has activated over 70 qualified treatment centers, with 40% having initiated or completed treatment for at least one patient. Commercial momentum is evidenced by 30 patient starts already scheduled for 2025.The company's cash position stood at $118.7M as of September 30, including $48M in restricted cash. Management expects current funds to last into Q1 2025 and anticipates reaching quarterly cash flow break-even in H2 2025, contingent on scaling to approximately 40 drug product deliveries per quarter and securing additional financing. Operating expenses showed improvement with R&D expenses decreasing to $23.2M from $58.5M YoY.The company has made significant progress in market access, with over half of U.S. states affirming coverage for LYFGENIA and multiple outcomes-based agreements in place with national commercial payers covering more than 200 million lives. Net loss for Q3 improved to $60.8M compared to $87.2M in the prior year.